Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,131.50 -19.06 (-1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 616,628
Open 1,150.00
Bid (Size) 1,050.00 (8)
Ask (Size) 1,128.05 (1)
Prev. Close 1,150.56
Today's Range 1,128.97 - 1,152.87
52wk Range 769.19 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
These stocks have generally delivered competitive returns. 
Via The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets

Performance

YTD
+25.03%
+25.03%
1 Month
+1.63%
+1.63%
3 Month
+12.95%
+12.95%
6 Month
+17.32%
+17.32%
1 Year
+36.21%
+36.21%

More News

Read More
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Via Benzinga
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
Via Benzinga
10 Bagger Stocks: Can You Find One?
Via Talk Markets
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
Via Benzinga
Exposures Product Safety
Regeneron Provides Update on Biologics License Application for Linvoseltamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
Via Benzinga
Analyst Ratings For Regeneron Pharmaceuticals
Via Benzinga
Alphabet Turns Twenty
Via Talk Markets
7 Stocks That Usually Benefit From a Recession
Via InvestorPlace
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
Via InvestorPlace
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Via InvestorPlace
Exposures Product Safety
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Healthcare Stocks Positioned for Possible Market Outperformance
Via InvestorPlace
Is Regeneron Pharmaceuticals Due for a Stock Split?
Via The Motley Fool
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Via Benzinga
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Via Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.